Compound class:
Synthetic organic
Comment: The structure for davelizomib was obtained from proposed INN list 129 (August 2023) where it is described as a proteasome inhibitor and antineoplastic agent. It is example I-1 in patent JP2021531302A. This patent encompasses use of claimed compounds for the treatment of multiple myeloma, and identifies its potential in MM that is resistant to treatment with the existing proteasome inhibitor bortezomib.
|
|
Classification | |
Compound class | Synthetic organic |
IUPAC Name |
2-[(4S)-2-[(1R)-1-[[2-[[(2S)-1-(2,4-difluorophenyl)azetidine-2-carbonyl]amino]acetyl]amino]-3-methylbutyl]-5-oxo-1,3,2-dioxaborolan-4-yl]acetic acid |
Database Links | |
CAS Registry No. | 2409841-51-4 (source: WHO INN record) |
GtoPdb PubChem SID | 485206008 |
PubChem CID | 147112102 |
Search Google for chemical match using the InChIKey | BMSAGHWUHGTMIV-ULQDDVLXSA-N |
Search Google for chemicals with the same backbone | BMSAGHWUHGTMIV |
UniChem Compound Search for chemical match using the InChIKey | BMSAGHWUHGTMIV-ULQDDVLXSA-N |
UniChem Connectivity Search for chemical match using the InChIKey | BMSAGHWUHGTMIV-ULQDDVLXSA-N |